Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Imatinib Mesylate × Other neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 192 Myeloid 140 Sarcoma 95 Gastrointestinal 78 Lymphoid 45 CNS 21 Thoracic 19 Dermatologic 14 Genitourinary 13 Other solid neoplasm 11 Tumor-Agnostic 9 Gynecologic 9 Breast 8 Head & Neck 7 Plasma cell 3 Endocrine 2 Classical hematology 2 Other neoplasm 1 Other 1

Conditions

Rare Malignant Neoplasm 1

Interventions

Cyclophosphamide 12 fludarabine phosphate 9 Peripheral Blood Stem Cell Transplantation 9 Busulfan 9 Biopsy 9 Whole-Body Irradiation 8 Surveys and Questionnaires 8 Polymerase Chain Reaction 7 Mycophenolic Acid 7 Tacrolimus 6 Gene Expression Profiling 6 Early Intervention, Educational 6 Colposcopy 6 fludarabine 5 Methotrexate 5 Melphalan 5 Educational Status 5 Decitabine 5 Cyclosporine 5 Celecoxib 5 Carboplatin 5 Antilymphocyte Serum 5 Aminolevulinic Acid 5 Sulindac 4 Radiotherapy 4 Patient Reported Outcome Measures 4 Paclitaxel 4 Microarray Analysis 4 Methods 4 Interviews as Topic 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡